Oppenheimer Upgrades Sarepta Therapeutics (SRPT) to Outperform
Tweet
Share
E-mailGet Alerts SRPT Hot Sheet
Price: $20.81 +3.33%
Rating Summary:
19 Buy, 18 Hold, 6 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 10 | New: 48
Rating Summary:
19 Buy, 18 Hold, 6 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 10 | New: 48
Join SI Premium – FREE
Oppenheimer analyst Hartaj Singh upgraded Sarepta Therapeutics (NASDAQ: SRPT) from Perform to Outperform with a price target of $180.00.
For an analyst ratings summary and ratings history on Sarepta Therapeutics click here. For more ratings news on Sarepta Therapeutics click here.
Shares of Sarepta Therapeutics closed at $131.70 yesterday.
You May Also Be Interested In
- Cantor Fitzgerald Upgrades Omeros Corp. (OMER) to Overweight, 'We May Have Underestimated Yartemlea'
- Kotak Upgrades Mankind Pharma Ltd (MANKIND:IN) to Buy (1)
- Morgan Stanley Upgrades Coal India Ltd (COAL:IN) to Overweight
Create E-mail Alert Related Categories
UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
